Compare Abeona Therapeutics Inc (ABEO) vs Hewlett Packard Enterprise Co (HPE) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abeona Therapeutics Inc vs Hewlett Packard Enterprise Co — how do they compare? Abeona Therapeutics Inc trades at $6.74 (market cap $373.32M), while Hewlett Packard Enterprise Co trades at $44.53 (market cap $57.56B). The key difference: Hewlett Packard Enterprise Co is far larger — about 154.2× Abeona Therapeutics Inc's market cap, and Hewlett Packard Enterprise Co pays a 1.31% dividend while Abeona Therapeutics Inc pays none. Which is the better fit depends on your goals.
| ABEO | HPE | |
|---|---|---|
Market Cap | $373.32M | $57.56B |
Sector | Health | Technology |
52-Week High | $7.23 | $56.14 |
52-Week Low | $4.17 | $19.81 |
Enterprise Value | $228.22M | $73.52B |
Dividend Yield | — | 1.31% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $6.31, down 1.41% today, with a bullish technical outlook supported by moving averages. The company reported Q1 2026 results with revenue growth and beat EPS expectations, while maintaining strong profitability margins. Recent news highlights expansion of treatment centers and new cell therapy licensing.
Outlook remains positive with analyst consensus favoring Buy ratings (66.67%), though high RSI indicates potential near-term overbought conditions. Key risks include negative operating cash flow and reliance on new treatment adoption. Upside depends on continued commercial execution and pipeline advancements.
HPE trades at $43.445, up 5.42% today, with a bearish technical signal despite recent earnings beats. Revenue grew to $34.3B in 2025, but net income fell sharply to $57M, pressuring margins. Analysts show a mixed consensus with a $69.69 price target, implying significant upside. The stock faces headwinds from high valuation multiples and volatile cash flows, though AI server demand and dividend payments offer support.
The outlook balances growth from AI infrastructure investments against execution risks and margin pressure. Upside hinges on sustained earnings outperformance and debt management, while downside risks include competitive threats and macroeconomic volatility. Institutional sentiment is cautiously optimistic given the high price target disparity.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About Hewlett Packard Enterprise Co
Hewlett Packard Enterprise is an information technology vendor that provides hardware and software to enterprises. Its primary product lines are compute servers, storage arrays, and networking equipment.
Read more on HPE →
